phentermine gh phentermine 15 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 15 mg - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine gh phentermine 40 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 40 mg - capsule, modified release - excipient ingredients: magnesium stearate; sodium polystyrene sulfonate; titanium dioxide; purified water; erythrosine; gelatin; iron oxide black; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide; ethanol absolute - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine gh phentermine 30 mg sustained release capsule blister pack
lupin australia pty limited - phentermine, quantity: 30 mg - capsule, modified release - excipient ingredients: magnesium stearate; sodium polystyrene sulfonate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; brilliant blue fcf; erythrosine; gelatin; iron oxide black - phentermine gh is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine gh can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
escitalup escitalopram (as oxalate) 20mg tablet blister pack
lupin australia pty limited - escitalopram oxalate -
escitalup escitalopram (as oxalate) 20mg tablet bottle
lupin australia pty limited - escitalopram oxalate -
escital escitalopram (as oxalate) 20mg tablet blister pack
lupin australia pty limited - escitalopram oxalate -
escital escitalopram (as oxalate) 20mg tablet bottle
lupin australia pty limited - escitalopram oxalate -
escitalopram-mppl escitalopram (as oxalate) 20mg tablet blister pack
lupin australia pty limited - escitalopram oxalate -
escitalopram-mppl escitalopram (as oxalate) 20mg tablet bottle
lupin australia pty limited - escitalopram oxalate -
escitalopram-lapl escitalopram (as oxalate) 20mg tablet blister pack
lupin australia pty limited - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - - treatment of major depression. - treatment of social anxiety disorder (social phobia). - treatment of generalised anxiety disorder. - treatment of obsessive-compulsive disorder.